Skip to content

A Study to Evaluate the Effectiveness of a Topical Unani Formulation Compared to Luliconazole 1 Percent Ointment in Treating Bahaq (Pityriasis Versicolor)

Therapeutic Evaluation of a Topical Unani Formulation in Pityriasis Versicolor (Bahaq) and Its Comparative Study with Luliconazole 1 Percent Ointment: A Randomized, Parallel Group, Open-Label, Standard-Controlled Clinical Trial - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087906
Enrollment
64
Registered
2025-05-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B360- Pityriasis versicolor

Interventions

Intervention1: A Topical Unani Formulation: Composition: Phitakri (Alum) Hartal (Arsenic disulhate) Gandhak (Sulphur) kharbaq (helleborusniger) topical, after mixing the powder in vinegar. Dosage of D

Sponsors

Government Nizamia Tibbi College and General Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age group above 16 to 45 years Sex: Both males & females Patient with any of the sign and symptoms of Bahaq (Pityriasis Versicolor) Hyper pigmented macule, Erythema, Pruritus on the lesion, Scaling / Desquamation. Presence of Malassezia furfur in the scrapings of the lesion

Exclusion criteria

Exclusion criteria: Patient with serious co-morbid medical condition and other fungal infection Participant who had received any systemic or topical antimycotic therapy within month of start of study Significant Pulmonary/Cardiovascular/ Hepato-renal Dysfunction Known cases of Immunocompromised states (HIV, AIDS, etc.) Malignancies Patient not willing to attend treatment schedule regularly Person, Individual with any active Psychiatric illness KoH mount test negative

Design outcomes

Primary

MeasureTime frame
Mycological cure rate of KOH examination of skin scrap (Direct Microscopy) at the end of 45 days.Timepoint: 45 Days

Secondary

MeasureTime frame
Improvement in subjective parameters (Hypopigmentation, Scaling & Itching) of skin lesions evaluated by an arbitrary grading scale, Total Sign & Symptom Score (TSSS) assessed on four point scale (0 absent, 1 mild, 2 moderate, 3 severe)Timepoint: 45 Days

Countries

India

Contacts

Public ContactDr Shahbaz Ahmed

Government Nizamia Tibbi College and General Hospital

ahmedfarhath66@gmail.com9848195067

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026